Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response

ACS Ahn, 2017, EGFR TKI combination with immunotherapy in non-small cell lung cancer, Expert Opin. Drug Saf., 16, 465, 10.1080/14740338.2017.1300656 Alomari, 2016, Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases, Cancer Immunol. Res., 4, 481, 10.1158/2326-6066.CIR-15-0238 Antonia, 2016, Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies, Am. Soc. Clin. Oncol. Educ. Book, 35, e450, 10.1200/EDBK_158712 Baxi, 2018, Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis, BMJ, 360, k793, 10.1136/bmj.k793 Benci, 2016, Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell, 167, 1540, 10.1016/j.cell.2016.11.022 Brogden, 2018, Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy, BMC Cancer, 18, 225, 10.1186/s12885-018-4134-y Champiat, 2017, Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1, Clin. Cancer Res., 23, 1920, 10.1158/1078-0432.CCR-16-1741 Chang, 2018, Microsatellite instability: a predictive biomarker for cancer immunotherapy, Appl. Immunohistochem. Mol. Morphol., 26, e15, 10.1097/PAI.0000000000000575 Chen, 2014, Non-small-cell lung cancers: a heterogeneous set of diseases, Nat. Rev. Cancer, 14, 535, 10.1038/nrc3775 Chen, 2015, Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation, J. Thorac. Oncol., 10, 910, 10.1097/JTO.0000000000000500 Dang, 2016, Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer, Expert. Rev. Anticancer. Ther., 16, 13, 10.1586/14737140.2016.1123626 De Simone, 2016, Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells, Immunity, 45, 1135, 10.1016/j.immuni.2016.10.021 Dela Cruz, 2011, Lung cancer: epidemiology, etiology, and prevention, Clin. Chest Med., 32, 605, 10.1016/j.ccm.2011.09.001 Ettinger, 2017, Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Cancer Netw., 15, 504, 10.6004/jnccn.2017.0050 FDA Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, 12, 298, 10.1038/nrc3245 Fuerst, 2018 Galon, 2007, The adaptive immunologic microenvironment in colorectal cancer: a novel perspective, Cancer Res., 67, 1883, 10.1158/0008-5472.CAN-06-4806 Galon, 2013, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, 39, 11, 10.1016/j.immuni.2013.07.008 Garcia-Diaz, 2017, Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression, Cell Rep., 19, 1189, 10.1016/j.celrep.2017.04.031 Gettinger, 2016, Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer, J. Clin. Oncol., 34, 2980, 10.1200/JCO.2016.66.9929 Goc, 2014, Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses, Oncoimmunology, 3, 10.4161/onci.28976 Hamm, 2016, Genomic and immunological tumor profiling identifies targetable pathways and extensive CD8+/PDL1+ immune infiltration in inflammatory breast cancer tumors, Mol. Cancer Ther., 15, 1746, 10.1158/1535-7163.MCT-15-0353 He, 2017, LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes, J. Thorac. Oncol., 12, 814, 10.1016/j.jtho.2017.01.019 Higgs, 2016 J, 2017, Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors Jenkins, 2018, Mechanisms of resistance to immune checkpoint inhibitors, Br. J. Cancer, 118, 9, 10.1038/bjc.2017.434 Kang, 2017, 28, 1388 Karanikas, 2007, Indoleamine 2, 3-dioxygenase (IDO) expression in lung cancer, Cancer Biol. Ther., 6, 1258, 10.4161/cbt.6.8.4446 Kouo, 2015, Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells, Cancer Immunol. Res., 3, 412, 10.1158/2326-6066.CIR-14-0150 Kowanetz, M., et al., OA20.01 tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. J. Thorac. Oncol. 12(1): p. S321-S322. Koyama, 2016, Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat. Commun., 7, 10.1038/ncomms10501 Lin, 2015, EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB, Biochem. Biophys. Res. Commun., 463, 95, 10.1016/j.bbrc.2015.05.030 Liu, 2017, Is CD47 an innate immune checkpoint for tumor evasion?, J. Hematol. Oncol., 10, 12, 10.1186/s13045-016-0381-z Luke, 2018, Preliminary antitumor and immunomodulatory activity of BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, in combination with nivolumab in patients with advanced cancers Malhotra, 2017, Current state of immunotherapy for non-small cell lung cancer, Transl. Lung Cancer Res., 6, 196, 10.21037/tlcr.2017.03.01 Mellemgaard, 2017, Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC, J. Clin. Oncol., 35, TPS2610, 10.1200/JCO.2017.35.15_suppl.TPS2610 Munn, 2007, Indoleamine 2, 3-dioxygenase and tumor-induced tolerance, J. Clin. Invest., 117, 1147, 10.1172/JCI31178 Oelkrug, 2014, Enhancement of T cell recruitment and infiltration into tumours, Clin. Exp. Immunol., 178, 1, 10.1111/cei.12382 Ott, 2019, T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028, J. Clin. Oncol., 37, 318, 10.1200/JCO.2018.78.2276 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Ramalingam, 2016, P 2.39: long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab: track: immunotherapy, J. Thorac. Oncol., 11, S241, 10.1016/j.jtho.2016.08.110 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Ribas, 2015, 33 Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017 Somasundaram, 2017, The next generation of immunotherapy: keeping lung cancer in check, J. Hematol. Oncol., 10, 87, 10.1186/s13045-017-0456-5 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A., 102, 15545, 10.1073/pnas.0506580102 Trojan, 2004, Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer, Lung Cancer, 44, 143, 10.1016/j.lungcan.2003.11.004 Voong, 2017, Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer, Ann. Transl. Med., 5, 376, 10.21037/atm.2017.06.48 Wang, 2002, Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness, Cancer Res., 62, 3581 Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat. Rev. Immunol., 15, 486, 10.1038/nri3862 Workman, 2003, The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells, Eur. J. Immunol., 33, 970, 10.1002/eji.200323382 Workman, 2004, Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo, J. Immunol., 172, 5450, 10.4049/jimmunol.172.9.5450 Xu, 2015, Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma, Int. Immunopharmacol., 29, 635, 10.1016/j.intimp.2015.09.017 Yu, 2007, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat. Rev. Immunol., 7, 41, 10.1038/nri1995